Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use

• Main Authors: António Cabral Lopes (Author), Olga Lourenço (Author), Sandra Morgado (Author), Andreia Gaspar (Author), Idalina Freire (Author), Inês Eusébio (Author), João Ribeiro (Author), Mafalda Silva (Author), Marta Mendes (Author), Olímpia Fonseca (Author), Rute Duarte (Author), Manuel Morgado (Author)
• Format: Book
• Published: MDPI AG, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), has shown demonstrated benefits for renal and cardiovascular outcomes in large clinical trials. However, short-term concerns regarding its impact on renal function and electrolyte balance exist. This study aimed to evaluate the short-term effects of dapagliflozin on renal function and electrolyte balance in patients newly prescribed the medication. A retrospective analysis of 246 patients who initiated dapagliflozin therapy was conducted. Serum creatinine, sodium, and potassium levels were measured at baseline (before dapagliflozin) and 5-8 days after initiation (endpoint). A Wilcoxon signed-rank test, Pearson's chi-square test, and Fischer's exact test were used for the data analysis. Glycemia and sodium levels were significantly higher at the baseline compared to the endpoint (<i>p</i> < 0.001). Conversely, creatinine and potassium levels were significantly higher at the endpoint than at the baseline (<i>p</i> < 0.001). The prevalence of hyponatremia and hyperkalemia were increased at the endpoint (17.5% vs. 10.2% and 16.7% vs. 8.9%, respectively). Although not statistically significant, a trend towards increased hyponatremia with the co-administration of furosemide was observed (<i>p</i> = 0.089). No significant association was found between potassium-sparing medications (<i>p</i> > 0.05) and hyperkalemia, except for angiotensin receptor blockers (<i>p</i> = 0.017). The combination of dapagliflozin and furosemide significantly increased the risk of acute kidney injury (AKI) at the endpoint (<i>p</i> = 0.006). Age, gender, and chronic kidney disease status did not significantly influence the occurrence of AKI, hyponatremia, or hyperkalemia (<i>p</i> > 0.05). These findings emphasize the importance of the close monitoring of renal function and electrolyte balance, particularly in the early stages of dapagliflozin therapy, especially in patients receiving diuretics or renin-angiotensin-aldosterone system inhibitors.

Item Description

10.3390/ph17040420
1424-8247